^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Dynastat (parecoxib)

    Company:
    Pfizer
    Drug class:
    COX2 inhibitor
    Related drugs:
    8d
    Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression. (PubMed, J Immunother Cancer)
    PCSK9 promoted HCC immune escape by upregulating SPP1 and PD-L1 via NOTCH3/FLI1 signaling. CRISPR ABE-mediated PCSK9 deficiency and PCSK9 inhibitor parecoxib may serve as effective strategies to inhibit HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • NOTCH3 (Notch Receptor 3) • SPP1 (Secreted Phosphoprotein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    PD-L1 expression
    |
    Dynastat (parecoxib)
    1m
    Ultrasound-Guided Transversus Abdominis Plane Block with Dexmedetomidine Combined with Ropivacaine Plus Diclofenac Sodium Suppository for Post-Cesarean Section Analgesia: A Non-Inferiority Randomized Controlled Trial (ChiCTR2500108775)
    P=N/A, N=120, Not yet recruiting, Hanzhong Central Hospital; Hanzhong Central Hospital
    New trial • Head-to-Head
    |
    Dynastat (parecoxib) • Sufenta (sufentanil)
    3ms
    PANDA: Study Comparing Dynastat and Parestat Pain Relief Medications for Patients After Breast Surgery (clinicaltrials.gov)
    P4, N=60, Not yet recruiting, University of Malaya
    New P4 trial • Head-to-Head
    |
    Dynastat (parecoxib)
    4ms
    Feasibility Study of Enhanced Recovery After Surgery (ERAS) Concept in Endoscopic Submucosal Dissection (ESD) for Upper Gastrointestinal Lesions <= 2 cm: A Prospective, Randomized, Single-Center, Non-Inferiority Study (ChiCTR2500104159)
    P=N/A, N=183, Not yet recruiting, General Hospital of Northern Theater Command; General Hospital of Northern Theater Command
    New trial • Head-to-Head
    |
    Dynastat (parecoxib)
    7ms
    Parecoxib in Total Knee Arthroplasty (clinicaltrials.gov)
    P4, N=40, Completed, University of Chile | Recruiting --> Completed | Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Apr 2024 --> Sep 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Dynastat (parecoxib)
    10ms
    Effect of parecoxib on postoperative cognitive function (delirium) in patients with hyperlipidemia: a single-center, randomized, double-blind controlled trial (ChiCTR2300073880)
    P4, N=442, Completed, Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University | Not yet recruiting --> Completed
    Trial completion
    |
    TNFA (Tumor Necrosis Factor-Alpha) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    Dynastat (parecoxib)
    11ms
    Effect of esketamine combined with parecoxib sodium on postoperative analgesia and inflammatory response in patients with thoracoscopic pulmonary resection (ChiCTR2500095107)
    P=N/A, N=80, Yongchuan Hospital affiliated to Chongqing Medical University; Yongchuan Hospital affiliated to Chongqing Medical University
    New trial
    |
    IL6 (Interleukin 6)
    |
    Dynastat (parecoxib)
    1year
    Preemptive Analgesic Efficacy of Parecoxib for Reducing Postoperative Pain in Gynecological Surgery (clinicaltrials.gov)
    P4, N=178, Completed, Rajavithi Hospital | Recruiting --> Completed
    Trial completion
    |
    Dynastat (parecoxib)
    1year
    Effect of Parecoxib sodium combined with esketamine and incision infiltration on postoperative analgesia and postoperative delirium (ChiCTR2400090230)
    P4, N=44, Completed, Taian City Central Hospital; Taian City Central Hospital
    New P4 trial
    |
    IL6 (Interleukin 6)
    |
    Dynastat (parecoxib) • Sufenta (sufentanil)
    1year
    PRECISE: Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    Dynastat (parecoxib)
    1year
    Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions (clinicaltrials.gov)
    P4, N=14, Not yet recruiting, Yung Shin Pharm. Ind. Co., Ltd.
    New P4 trial
    |
    Dynastat (parecoxib)
    1year
    Parecoxib Enhances Resveratrol against Human Colorectal Cancer Cells through Akt and TXNDC5 Inhibition and MAPK Regulation. (PubMed, Nutrients)
    This study presents evidence that parecoxib enhances the anti-cancer power of resveratrol in DLD-1 colorectal cancer cells via the inhibition of TXNDC5 and Akt signaling and enhancement of JNK/p38 MAPK pathways. Parecoxib may be provided as an efficient drug to sensitize colorectal cancer by resveratrol.
    Journal
    |
    TXN (Thioredoxin) • MAPK8 (Mitogen-activated protein kinase 8)
    |
    Dynastat (parecoxib)